Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the ...

PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company, which engages in the development of transformative solutions in urology. It manufactures and sells the AquaBeam Robotic ...

Learn more about whether NovoCure Limited or PROCEPT BioRobotics Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

TD Cowen lowered the firm’s price target on Procept BioRobotics (PRCT) to $85 from $99 and keeps a Buy rating on the shares. The firm notes sales topped estimates as the Hydros rollout continues ...

Good afternoon and welcome to Procept Biorobotics fourth quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes.

A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com/. The webcast will be ...

PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company’s HYDROS robotic system and consumables ...

Analysts' ratings for PROCEPT BioRobotics (NASDAQ:PRCT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings ...

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) by 4.9% in the fourth quarter, according to the company in its most recent ...

PROCEPT BioRobotics SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing ...